ObjectiveSince 2016, the Chinese government has been regularly implementing the National Reimbursement Drug List Negotiation (NRDLN) to improve the accessibility of drugs. In the second round of NRDLN
ObjectiveThe National Drug Price Negotiation (NDPN) has significantly reduced the prices and improved the nationwide availability of novel anticancer drugs (NADs) in China. However, geographical dispa
ObjectiveThe National Drug Price Negotiation (NDPN) has significantly reduced the prices and improved the nationwide availability of novel anticancer drugs (NADs) in China. However, geographical dispa
